Astal Laboratories Limited (NSE/BSE: **ASTAL**; formerly **Macro International Limited**) is an integrated Indian pharmaceutical company specializing in the manufacturing and trading of **Active Pharmaceutical Ingredients (APIs)**, **Bulk Drugs**, **Intermediates**, and **Specialty Chemicals**. Following a strategic takeover in **2022**, the company pivoted from financial services to the life sciences sector, officially rebranding in **May 2024** to reflect its new core identity. --- ### **Strategic Transformation and Acquisition-Led Growth Model** Astal Laboratories employs a "**Grow Faster Through Acquisitions**" strategy to rapidly scale its manufacturing footprint, enhance technical capabilities, and diversify its product portfolio. * **Sriven Pharmachem India Private Limited (SPIPL) Acquisition:** In **January 2026**, Astal completed a **100% acquisition** of **SPIPL** via a **1:1 share swap**. This milestone is projected to expand production capacity **four-fold**, allowing the company to execute larger, more complex global orders. * **Manufacturing Footprint Expansion:** * **Raichur, Karnataka:** Acquired a pharmaceutical intermediates plant from **Shree Venus Health Sciences** in **October 2024**. * **Vishakhapatnam, Andhra Pradesh:** In **July 2024**, the Board approved the purchase or lease of a manufacturing facility from **CPR Laboratories Private Limited**. * **Vertical Integration:** By consolidating these assets, the company aims to achieve **economies of scale** in raw material procurement and utilize shared infrastructure for **effluent treatment**, warehousing, and utilities. --- ### **High-Value Therapy Diversification and Global Market Access** The company is moving beyond basic intermediates into high-margin advanced therapies and regulated international markets. * **Cell & Gene Therapy (CAR-T):** In **December 2025**, Astal signed a Letter of Intent (LOI) with Switzerland-based **Immuna Therapeutics GmbH**. This grants Astal exclusive Indian rights to next-generation **CAR-T cell therapies**, with an estimated incremental revenue potential of **₹300 crore**. * **European Market Entry:** In **November 2025**, the company achieved **REACH Compliance Certification**, a mandatory requirement for exporting specialty chemicals to the **European Union**. This immediately resulted in an LOI for **60 tonnes** of **Piroctone Olamine** from a Swiss distributor. * **Radiology and Contrast Media:** Astal entered the diagnostic segment in **August 2023** by launching **Iopromide USP** via a 5-year contract manufacturing agreement with **Vibgyor Drugs Pvt. Ltd.**, targeting a **20% share** of the path lab market. --- ### **Financial Performance and Capital Structure** Astal has demonstrated aggressive top-line growth, though recent profitability has been impacted by transition costs and expansion investments. **Three-Year Financial Summary:** | Fiscal Year | Turnover (INR) | Net Profit (INR) | Growth Notes | | :--- | :--- | :--- | :--- | | **FY 2024–25** | **₹102.70 Crore** | **₹69.91 Lacs** | Sustained revenue above ₹100Cr | | **FY 2023–24** | **₹100.76 Crore** | **₹4.91 Crore** | **589.82%** Revenue increase YoY | | **FY 2022–23** | **₹35.85 Crore** | **₹1.20 Crore** | Initial transition phase | **Capital and Fundraising Status (as of March 2026):** * **Paid-up Capital:** **₹42.22 Crore** (consisting of **4,22,15,632** equity shares at **₹10** par value). * **Authorized Share Capital:** Increased to **₹50 Crore** in **October 2025** to accommodate growth. * **Borrowing & Investment Limits:** Expanded to **₹500 Crore** to support the acquisition pipeline. * **Preferential Allotments:** Issued **58,56,000** shares to non-promoters at premiums of **₹18–₹20** per share. * **Convertible Warrants:** Initiated a raise of **₹22.88 Crore** through **57,19,930** warrants, with the promoter group (**Aceso Research Labs LLP**) committing to **16,40,000** units. --- ### **Operational Infrastructure and R&D Capabilities** The company leverages its location in **Hyderabad**, the "Bulk Drug Capital of India," to access a deep talent pool and specialized infrastructure. * **R&D Center:** Through its subsidiary, Astal operates a dedicated **R&D center in Hyderabad** focused on **non-infringing process development** and analytical innovation. * **Quality Standards:** Operations adhere to **GMP (Good Manufacturing Practice)**, **ISO**, and **EHS (Environment, Health, and Safety)** certifications to streamline audits for global clients. * **CRAMS/CMO Positioning:** The company is positioning itself as a mid-sized **Contract Research and Manufacturing Services (CRAMS)** provider capable of multi-step synthesis and custom development. --- ### **Risk Profile and Regulatory Challenges** Investors should note specific regulatory hurdles and systemic industry risks currently facing the company. * **Regulatory Non-Compliance:** The company is currently seeking a relaxation from **SEBI ICDR Regulations (Regulation 159)**. This stems from an unauthorized sale of **23 shares** by a broker (**IIFL**) from the promoter’s account in **June 2024** to recover unpaid charges. This technical violation has delayed the allotment of **1,640,000** warrants to the promoter. * **Supply Chain Vulnerability:** Like much of the Indian pharma sector, Astal faces a high dependency on **China** for approximately **80%** of raw **API requirements**. Geopolitical shifts or environmental shutdowns in China can lead to significant price volatility. * **Market Integrity:** The prevalence of **spurious or substandard drugs** (estimated at **20-25%** of the Indian domestic market) poses a persistent reputational and competitive risk. * **Internal Controls:** To mitigate these risks, the company employs an **External Independent Agency** for internal control audits, overseen by an **Independent Audit Committee** and the Board of Directors. --- ### **Strategic Outlook** Astal Laboratories is focused on **vertical integration** and **cost optimization**. By consolidating functions post-acquisition, the company aims to reduce per-unit conversion costs and enhance bargaining power with global suppliers. The transition from a finance-led entity to a high-tech pharmaceutical manufacturer is nearly complete, with the current focus shifting toward **regulated market exports (USA, Europe, Japan)** and the commercialization of **advanced cell therapies**.